基尼化物和哈尔帕戈赛德功能化氧化纳米颗粒作为潜在的神经保护剂
Rosa Martha Pérez Gutiérrez1, Luis Miguel Rodríguez-Serrano2, José Fidel Laguna-Chimal2
1Natural Products Research Laboratory, Higher School of Chemical Engineering and Extractive Industries, National Polytechnic Institute (IPN), Av. National Polytechnic Institute S/N, Mexico City 07708, Mexico.
International journal of molecular sciences
|April 27, 2024
概括
与纳米颗粒 (GH/CeO2 NPs) 结合的基尼化物和哈帕戈化物在治疗阿尔茨海默病 (AD) 中显示出有前途. 这种新的治疗方法有效地减少了AD模型中的蛋白质聚合,并增强了AD模型中的记忆力.
科学领域:
- 神经科学是一个神经科学.
- 材料科学 材料科学 材料科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是蛋白质聚合和氧化应激.
- 乙胆酶在AD病理学中发挥着关键作用.
- 基尼化物和化物 (GH) 是已知的神经保护剂,而纳米粒子 (CeO2 NPs) 具有抗氧化特性.
研究的目的:
- 研究GH/CeO2NP在改善AD病变发生的治疗潜力.
- 在AlCl3诱导的AD小鼠模型和体外试验中评估GH/CeO2NP对蛋白质聚合和认知功能的影响.
主要方法:
- 用光谱分析来描述GH/CeO2NP的特征.
- 在体外测试以评估Tau和粉样β (Aβ1-42) 聚合的抑制.
- 对乙胆酶 (AChE) 和丁胆酶 (BuChE) 抑制的评估.
- 在AlCl3诱导的AD小鼠中评估记忆和认知功能.
主要成果:
- 发现GH/CeO2NP是稳定的,纳米大小,球形和无形的,具有完全的GH封装.
- GH/CeO2 NPs,CeO2 NPs,和多尼佩西尔抑制了纤维的形成,蛋白质聚合和ACHE/BuChE活动.
- 在AD小鼠中GH/CeO2NP治疗降低了Aβ1-42,改善了记忆力和认知协调.
结论:
- 结合的虹膜体和纳米颗粒显示出显著的化学保护作用.
- GH/CeO2 NP显示了通过减少氨基胺基因路径和抑制AChE/BuChE来缓解AD病变的潜力.
- 这项研究为开发神经退行性疾病的新治疗策略提供了基础.
相关概念视频
The Blood-brain Barrier
Overview
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...


